Positive News Sentiment NASDAQ:CMPS COMPASS Pathways - CMPS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. $10.08 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$9.88▼$10.2450-Day Range$7.75▼$10.8552-Week Range$6.54▼$21.50Volume361,756 shsAverage Volume271,322 shsMarket Capitalization$429.71 millionP/E RatioN/ADividend YieldN/APrice Target$34.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media COMPASS Pathways MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside366.3% Upside$47.00 Price TargetShort InterestBearish10.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.92) to ($2.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector905th out of 989 stocksPharmaceutical Preparations Industry436th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, COMPASS Pathways has a forecasted upside of 366.3% from its current price of $10.08.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.77% of the outstanding shares of COMPASS Pathways have been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 2.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPS. Previous Next 3.8 News and Social Media Coverage News SentimentCOMPASS Pathways has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for COMPASS Pathways this week, compared to 1 article on an average week.Search Interest44 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat Follows20 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders24.85% of the stock of COMPASS Pathways is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.54% of the stock of COMPASS Pathways is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.92) to ($2.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About COMPASS Pathways (NASDAQ:CMPS) StockCOMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Stock News HeadlinesMarch 14, 2023 | markets.businessinsider.comCOMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant DepressionMarch 12, 2023 | finance.yahoo.com10 Best Psychedelic Stocks to Buy According to Hedge FundsMarch 24, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and COMPASS Pathways (CMPS)March 2, 2023 | finance.yahoo.comCOMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor ConferenceMarch 2, 2023 | finance.yahoo.comCOMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finance.yahoo.comAnorexia is the deadliest psychiatric disorder. Could psychedelics help?March 1, 2023 | finance.yahoo.comCompass Pathways Plc (CMPS) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 1, 2023 | finance.yahoo.comQ4 2022 Compass Pathways PLC Earnings CallFebruary 28, 2023 | finance.yahoo.comCOMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business HighlightsFebruary 28, 2023 | finance.yahoo.comCOMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business HighlightsFebruary 27, 2023 | msn.comEarnings Preview: Compass PathwaysFebruary 24, 2023 | finance.yahoo.comCOMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023February 20, 2023 | finance.yahoo.com7 Long-Term Stocks to Buy With Your Tax RefundFebruary 16, 2023 | msn.comCybin, Compass Pathways Among Top Psychedelic Movers Of TodayFebruary 8, 2023 | benzinga.comCOMPASS Pathways And The Economic Outlook For 2023January 26, 2023 | seekingalpha.comCompass Pathways Takes On PsychedelicsJanuary 13, 2023 | finance.yahoo.comAll You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong BuyJanuary 11, 2023 | finance.yahoo.comAre Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?December 12, 2022 | benzinga.comMagic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So FarDecember 9, 2022 | msn.comPsychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To CommentsDecember 8, 2022 | msn.comCompass Pathways, Mind Medicine Among Top Psychedelic Movers Of TodayNovember 29, 2022 | finance.yahoo.com3 Big Trends Shaking Up Psychedelic StocksNovember 28, 2022 | finance.yahoo.comCOMPASS Pathways to participate in upcoming Evercore ISI HealthCONx ConferenceNovember 4, 2022 | finance.yahoo.comREFILE-Magic mushroom compound shows promise as depression treatment in key studyNovember 3, 2022 | msn.comCompass Pathways: Q3 Earnings InsightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Company Calendar Last Earnings2/28/2023Today3/24/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMPS CUSIPN/A CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees116Year Founded2016Price Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$120.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+245.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.56% Return on Assets-39.25% Debt Debt-to-Equity RatioN/A Current Ratio12.29 Quick Ratio12.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book2.37Miscellaneous Outstanding Shares42,630,000Free Float32,038,000Market Cap$429.71 million OptionableNot Optionable Beta2.46 Social Links Key ExecutivesMr. George Jay Goldsmith (Age 68)Exec. Chairman & Co-Founder Comp: $943.52kDr. Ekaterina Malievskaia M.D. (Age 55)Co-Founder, Chief Innovation Officer & Exec. Director Comp: $669.13kDr. Guy GoodwinChief Medical OfficerMr. Kabir Nath M.A.M.B.A., Chief Exec. OfficerMr. Michael F. Falvey (Age 63)Chief Financial Officer Dr. Greg Ryslik Ph.D.Exec. VP of AI, Engineering, Digital Health Research & TechnologyMr. Stephen D. SchultzSr. VP of Investor RelationsMr. Matthew OwensGen. Counsel & Chief Legal OfficerMr. Christopher WilliamsChief Communications OfficerMs. Anne BenedictChief People OfficerMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSAllakosNASDAQ:ALLKConcert PharmaceuticalsNASDAQ:CNCEArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsMorgan StanleySold 58,360 shares on 2/15/2023Ownership: 0.768%Millennium Management LLCSold 77,204 shares on 2/15/2023Ownership: 0.281%PFS Investments Inc.Bought 7,157 shares on 2/15/2023Ownership: 0.133%Alps Advisors Inc.Bought 5,764 shares on 2/15/2023Ownership: 0.068%Putnam Investments LLCBought 3,930 shares on 2/14/2023Ownership: 0.404%View All Insider TransactionsView All Institutional Transactions CMPS Stock - Frequently Asked Questions Should I buy or sell COMPASS Pathways stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPS shares. View CMPS analyst ratings or view top-rated stocks. What is COMPASS Pathways' stock price forecast for 2023? 5 equities research analysts have issued 12 month price targets for COMPASS Pathways' stock. Their CMPS share price forecasts range from $19.00 to $120.00. On average, they anticipate the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 368.6% from the stock's current price. View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts. How have CMPS shares performed in 2023? COMPASS Pathways' stock was trading at $8.03 on January 1st, 2023. Since then, CMPS stock has increased by 24.9% and is now trading at $10.03. View the best growth stocks for 2023 here. When is COMPASS Pathways' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our CMPS earnings forecast. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) issued its earnings results on Tuesday, February, 28th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.08. What ETFs hold COMPASS Pathways' stock? ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Psyk Etf (PSYK), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Putnam Sustainable Future ETF (PFUT) and Grizzle Growth ETF (GRZZ).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and When did COMPASS Pathways IPO? (CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is COMPASS Pathways' stock symbol? COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS." Who are COMPASS Pathways' major shareholders? COMPASS Pathways' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (2.89%), Susquehanna International Group LLP (0.00%), Morgan Stanley (0.77%), Sumitomo Mitsui Trust Holdings Inc. (0.75%), Nikko Asset Management Americas Inc. (0.75%) and Renaissance Technologies LLC (0.43%). Insiders that own company stock include David Y Norton and Ekaterina Malievskaia. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is COMPASS Pathways' stock price today? One share of CMPS stock can currently be purchased for approximately $10.03. How much money does COMPASS Pathways make? COMPASS Pathways (NASDAQ:CMPS) has a market capitalization of $427.58 million. The company earns $-91,500,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. How many employees does COMPASS Pathways have? The company employs 116 workers across the globe. How can I contact COMPASS Pathways? The official website for the company is www.compasspathways.com. The company can be reached via phone at 716-676-6461 or via email at ir@compasspathways.com. This page (NASDAQ:CMPS) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.